Genf
Switzerland
15
2022-09-08
The entities that hold a legal rights for patent applications filed by inventor Deloche Catherine:
Catherine Deloche from Genf, CH has applied for patents for these inventions. The list has both pending applications and granted patents:
Use For JNK Inhibitor Molecules For Treatment Of Various Diseases
#2 | 2020-07-02JNK Inhibitor Molecules For Treatment Of Various Diseases
#3 | 2020-03-26Use for JNK inhibitor molecules for treatment of various diseases
#4 | 2019-02-28Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
#5 | 2018-06-21New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment
#6 | 2017-10-12Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
#7 | 2017-05-18Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various Diseases
#8 | 2017-05-11Use for JNK Inhibitor Molecules for Treatment of Various Diseases
#9 | 2017-03-02JNK inhibitor molecules for treatment of various diseases
#10 | 2016-07-14Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
#11 | 2016-04-28New Use for JNK Inhibitor Molecules for Treatment of Various Diseases
#12 | 2016-03-31USE OF CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR THE TREATMENT OF CHRONIC OR NON-CHRONIC INFLAMMATORY EYE DISEASES
#13 | 2015-05-14Novel JNK Inhibitor Molecules for Treatment of Various Diseases
#14 | 2014-10-16Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye Syndrome
#15 | 2013-12-19Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
577306 ⎘